Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.98
- Piotroski Score 2.00
- Grade N/A
- Symbol (ATAI)
- Company Atai Life Sciences N.V.
- Price $1.61
- Changes Percentage (17.52%)
- Change $0.24
- Day Low $1.43
- Day High $1.65
- Year High $2.85
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
- Last Earnings 08/08/2018
- Ex-Dividend for 5/16 Dividend 08/27/2018
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.21
- Trailing P/E Ratio -6.62
- Forward P/E Ratio -6.62
- P/E Growth -6.62
- Net Income $-40,224,000
Income Statement
Quarterly
Annual
Latest News of ATAI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ATA IMS Berhad (KLSE:ATAIMS) investors are sitting on a loss of 88% if they invested three years ago
Long-term shareholders of ATA IMS Berhad have faced significant losses, with the share price down 88% in three years. Revenue dropped 79% annually, leading to a 24% decline in share price each year. I...
By Yahoo! Finance | 1 month ago -
Billionaire Lee Cooperman Says The Market Is Expensive But Elevance Health, Inc. (ATAI) Is Cheap
Leon Cooperman discusses cheap stocks in a CNBC interview, highlighting his outlook on the economy and stock valuations. Elevance Health, Inc. (ATAI) stands out among these stocks due to its expansion...
By Yahoo! Finance | 2 months ago -
Chiefs Rookie Kingsley Suamataia Plays Well In Loss To His Cousin's Lions
Kansas City Chiefs' Kingsley Suamataia faced his cousin Penei Sewell's team, the Detroit Lions, in a preseason game. Suamataia impressed as the starting left tackle, holding his own against Lions' bac...
By Forbes | 2 months ago
